Iovance Biotherapeutics/IOVA

$11.87

-0.42%
-
1D1W1MYTD1YMAX

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Ticker

IOVA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Frederick Vogt

Employees

557

Headquarters

San carlos, United States

IOVA Metrics

BasicAdvanced
$3.32B
Market cap
-
P/E ratio
-$1.89
EPS
0.64
Beta
-
Dividend rate
$3.32B
0.64497
$18.33
$3.21
9.24M
2.791
2.697
0.171
0.171
-61.49%
-81.91%
-71.47%
2,793.07
5.209
9.345
23.78%

What the Analysts think about IOVA

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
119.04% upside
High $34.00
Low $19.00
$11.87
Current price
$26.00
Average price target

IOVA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-29,075% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$400K
0%
Net income
$-116.3M
2.29%
Profit margin
-29,075%
2.29%

IOVA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.28%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.50
-$0.47
-$0.46
-$0.45
-
Expected
-$0.74
-$0.80
-$0.45
-$0.43
-$0.42
Surprise
-32.87%
-40.99%
1.25%
4.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Iovance Biotherapeutics stock?

Iovance Biotherapeutics (IOVA) has a market cap of $3.32B as of April 17, 2024.

What is the P/E ratio for Iovance Biotherapeutics stock?

The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of April 17, 2024.

Does Iovance Biotherapeutics stock pay dividends?

No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Iovance Biotherapeutics dividend payment date?

Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Iovance Biotherapeutics?

Iovance Biotherapeutics (IOVA) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Iovance Biotherapeutics stock price target?

The target price for Iovance Biotherapeutics (IOVA) stock is $26, which is 119.04% above the current price of $11.87. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Iovance Biotherapeutics stock

Buy or sell Iovance Biotherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing